QuantHealth

We’ve arrived at ESMO 2025 in Berlin! Come meet the QuantHealth team and see firsthand how we're using AI to de-risk clinical trials in Oncology. 📅 Want to connect? Email us at [email protected] #ESMO2025 #Oncology

Every first-in-class program faces blind spots. The question is: how costly will they be? On October 8 at 11:30 am ET, QuantHealth’s experts, Adam Petrich, MD, and Omri Matalon (PhD) Matalon, will explore how QuantHealth’s AI simulations are helping teams reduce blind spots and de-risk development where conventional methods fall short. In “Can AI Give Us an Edge in First-in-Class Programs?” expect to hear: - Why AI often fails in the most innovative programs - How QuantHealth enables stronger protocols and smarter go/no-go calls - What leading teams are doing to accelerate first-in-class development with confidence If you’re building the therapies of tomorrow, this conversation could change how you approach the next high-risk decision. 🔗 Secure your spot now! https://lnkd.in/dppye6CE

Looking forward to meeting you at ESMO 2025 in Berlin, October 17-18!    Come meet the QuantHealth team and see firsthand how we're using AI to de-risk clinical trials in Oncology.    📅 Want to connect? Book a meeting here: https://lnkd.in/dGZP9VUD     #ESMO2025 #Oncology 

🚀 We’re thrilled to announce that QuantHealth has secured a strategic investment from Sanofi Ventures to accelerate the adoption of AI-driven clinical trials! This partnership strengthens our mission: to bring scalable, patient-level simulations and digital twin technologies to the forefront of drug development. With this investment, our total funding reaches $30M, enabling us to push harder on predictive modeling, protocol optimization, and reducing risk for our pharma partners' clinical pipelines. We’re honored to welcome Cris De Luca (Partner, Sanofi Ventures) as an observer to our Board, while working alongside incredible leaders like Emmanuel Frenehard and Lionel Bascles. This deepens our strategic relationship with Sanofi as they continue transforming R&D via AI. A huge thank you to our team, collaborators, and supporters — this is just the beginning of what we can do together. #AI #DigitalTwins #ClinicalTrials #PharmaInnovation #HealthTech #QuantHealth https://lnkd.in/dNHbNv_W

In Puck New’s “Your A.I. on Drugs” by Ian Krietzberg, our CEO & Co-founder Orr Inbar explains how QuantHealth uses AI to reduce costly trial failures and accelerate R&D, saving time, money, and getting therapies to patients faster. 

First-in-class therapies hold immense promise where no existing treatment is available. But they also face the toughest barriers: limited precedent, scarce datasets, and decisions that can make or break a program. The challenge is how to de-risk innovation without slowing it down. Join Adam Petrich, MD (Chief Medical Officer, QuantHealth) and Omri Matalon (PhD) (SVP R&D, QuantHealth) in our webinar, “Can AI Give Us an Edge in First-in-Class Programs?” as they explore: - Why conventional AI falls short in high-uncertainty programs - How QuantHealth’s approach closes evidence gaps and strengthens trial design - What success looks like when AI de-risks go/no-go decisions and accelerates timelines 📅 October 8, 2025 | 11:30am ET If you’re leading R&D or clinical strategy, this is your opportunity to see how QuantHealth can bring clarity to the riskiest programs. 🔗 Register now! https://lnkd.in/dppye6CE

Why does conventional AI often fail in first-in-class drug development? Because first-in-class means entering unknown territory: limited data, no precedent, and risk at every decision point. Traditional AI models trained on existing data struggle to provide insights where evidence is scarce. QuantHealth’s approach is built for this very challenge. By leveraging virtual patient simulations and advanced predictive models, it closes evidence gaps, supports stronger protocol design, and helps teams make smarter go/no-go decisions earlier. Join us for “Can AI Give Us an Edge in First-in-Class Programs?” with Adam Petrich, MD, Chief Medical Officer at QuantHealth, and Omri Matalon (PhD), SVP R&D at QuantHealth, as we dive deeper into QuantHealth’s unique approach and real-world examples of success.  📅 October 8, 2025 | 11:30am ET 🔗 Secure your spot now! https://lnkd.in/dppye6CE

Looking forward to connecting at BioTechX Europe 2025 in Basel, October 6-8!  Meet the QuantHealth team and see how we're applying AI to de-risk clinical trials across therapeutic areas. 📅 Want to connect? Book a meeting here: https://lnkd.in/dXgyAxia 

How will tariffs impact pharma, patients, and the future of drug development? Our CEO & Co-founder, Orr Inbar, sat down with pharmaphorum to discuss the potential effects of tariffs on pharmaceutical imports into the US, and why now, more than ever, drug developers must embrace innovation. 🔗 Read the full interview here: https://lnkd.in/dtS4F9Y3 #DrugDevelopment #AI #ClinicalTrials #Pharma #QuantHealth